Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Phase III Trial Under Way For Icagen's Sickle Cell Product

Feb. 23, 2005

By Aaron Lorenzo

Phase III Trial Under Way For Icagen's Sickle Cell Product

Feb. 23, 2005

By Aaron Lorenzo

FDA Committee Members Vote To Let Vioxx Return To Market

Feb. 22, 2005

By Aaron Lorenzo

FDA Committee Members Vote To Let Vioxx Return To Market

Feb. 22, 2005

By Aaron Lorenzo

FDA Doctor Questions Need For Any Drugs From the COX-2 Class

Feb. 18, 2005

By Aaron Lorenzo

FDA Doctor Questions Need For Any Drugs From the COX-2 Class

Feb. 18, 2005

By Aaron Lorenzo

Pfizer Defends Celebrex As FDA Meets On Safety Of COX-2 Class

Feb. 17, 2005

By Aaron Lorenzo

Pfizer Defends Celebrex As FDA Meets On Safety Of COX-2 Class

Feb. 17, 2005

By Aaron Lorenzo

Crawford Receives Bush's Nomination As FDA Head

Feb. 16, 2005

By Aaron Lorenzo

Crawford Receives Bush's Nomination As FDA Head

Feb. 16, 2005

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...